CYCLOCORT
LOE ApproachingNDATOPICALLOTION
Approved
Jun 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYCLOCORT is a topical corticosteroid lotion approved in 1988 for inflammatory and pruritic dermatological conditions. The exact indication profile is not specified in available data, but topical corticosteroids are standard-of-care for eczema, psoriasis, dermatitis, and other inflammatory skin disorders. It works by suppressing local immune response and reducing inflammation at the site of application.
LOE Approaching
LOE trajectory signals transition from brand defense to managed decline; commercial teams may be rightsizing or pivoting to adjacent dermatology assets.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CYCLOCORT presents limited career growth opportunity given its LOE-approaching status and zero linked job openings. Roles available are primarily commercial and sales-focused, with emphasis on defensive market share management rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on CYCLOCORT at Astellas? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.